Call (212) 245-5801 
|
| Home | | | | | | | | | | | Testimonials | | | Contact Us |
|
Posted on 10/1/2016 by Manhattan Maxillofacial Surgery Group |
| October 31, 2012
It is with great pleasure that we invite you to our study club meeting. The goal of the study club is to provide you with a cutting-edge educational resource and an opportunity to receive CE credits. We meet several times a year and host renowned speakers with presentations on current oral health topics. The tuition for the course is COMPLIMENTARY As a sign of our appreciation for your continued support Dr. Del Valle & Dr. Shahgoli are happy to provide the registration fee and dinner for attendees free of charge. Topic Current Strategies for Prevention and treatment if Osteonecrosis of the Jaw Presenter Kenneth E. Fleisher DDS Date Wednesday, January 23, 2012 Time 6:30 PM – 9:30 PM Location Dopo Teatro, 125 West 44th Street, New York, NY 10036 3 CE Credits. To ensure your spot respond by January 7 to Carly Siegel or (917) 675-0109. Bone health and maintenance of bone integrity are important concerns during comprehensive cancer care and management of osteoporosis. Bisphosphonates (BPs) are widely used for the prevention and treatment of osteoporosis and skeletal complications associated with metastatic cancer and multiple myeloma. We can anticipate greater concerns related to oral health and antiresorptive therapy based on reports that characterize the efficacy of these drugs for metastatic disease and osteoporosis, the expanded use of BPs as preventive therapy, the increased life expectancy of patients who use these drugs and recent evidence of osteonecrosis not related to bisphosphonate medications. The growing incidence of ONJ cases highlights the importance of interdisciplinary management for dentists and physicians. Although the occurrence of ONJ is considered rare, it may have a broad health impact and has created numerous dilemmas in patient management among oncologists, endocrinologists, rheumatologists and dentists. Clinicians should be aware of paradigm shifts that are developing in the pathogenesis, diagnosis, risk assessment, prevention and treatment of ONJ. |
|
